Harmony Biosciences Holdings is a holding company. Through its subsidiary, Harmony Biosciences, LLC, Co. is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological disorders. Co.'s product, WAKIX (pitolisant), is a molecule with a mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors. WAKIX has been approved for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. Also, WAKIX has been approved for the treatment of cataplexy in adult patients with narcolepsy. The HRMY average annual return since 2020 is shown above.
The Average Annual Return on the HRMY average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether HRMY average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the HRMY average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|